Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by hmmmmmmmmon Jan 12, 2023 2:03pm
185 Views
Post# 35219057

RE:RE:RE:RE:RE:1 Patient enrolled per month..

RE:RE:RE:RE:RE:1 Patient enrolled per month..I was not truly asking for MM calculations as there are dozens he's posted here that get more riduclous with the passing of each million dollar month.

The question of assigning it a value is not the question at hand. The question is how we see any value with this management and their approach?

In April the Tigris trial will be 3 years old. So, 50 patients in 33 months. an average of 1.5 patients a month.

Some would say Covid is the reason for such terrible recruitment numbers. But we've just seen them admit to 1 patient per month over the last 2 months- and that is with 16+ sites, without Covid disruptions, during a historic flu season.

At 1 million dollars a month it is unsustainable. Each time they raise money they dilute the stock by roughly 10%. 

At the 1.5 per month rate it would take 66.6 more months to finish the trial.
That 5.5 years. At 4.5 more raises.. with a loss of 10% per- it is unsustainable.

If you ran it with the numbers for the last 6 months from the AGM to now- it averages 2 patients per month. That would take 50 months to completion. 4+ years and all the dilution that goes with it.

So my honest answer is- we can't get there with this management. 

They tell us how well their "confrence calls" with sites are going- when for months we've been asking for Kellum to have boots on the ground- going from site to site and like it matters, and make sites feel like someone actually cares if patients are enrolled. I mean this is supposed to save lives after all!

It is not working. The numbers are black and white. Leadership needs to be replaced for not recognizing/ caring and righting the ship/ doing their job. 

It is now the BOD job. Before Management's lack of ability causes this to be sold off for pennies on the dollar.



<< Previous
Bullboard Posts
Next >>